Cite
MLA Citation
Jacob D Soumerai et al.. “Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.” Lancet, vol. 8, no. 12, 2021, pp. e879–e890. http://access.bl.uk/ark:/81055/vdc_100146344171.0x00000f